Antitumor agent
US9125915B2 · kind B2 · utility
55Cited by
3References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 28, 2013 |
| Grant date | Sep 8, 2015 |
| Priority date | — |
| Expiry date | May 28, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method of inhibiting binding between acetylated histone and a bromodomain-containing protein in a mammal, as well as a method of shrinking or killing of cancer cells expressing a bromodomain-containing protein or inhibiting the growth of cancer cells expressing a bromodomain-containing protein in a mammal. The methods involve administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof to the mammal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.